Incidence and Characteristics of Adverse Events after COVID-19 Vaccination in a Population-Based Programme

Bonzano, Laura; Djurić, Olivera; Mancuso, Pamela; Fares, Lidia; Brancaccio, Raffaele; Ottone, Marta; Bisaccia, Eufemia; Vicentini, Massimo; Cocconcelli, Alessia; Motolese, Alfonso; Boyko, Rostyslav; Rossi, Paolo Giorgi; Motolese, Alberico

doi:10.3390/vaccines10071111

Cited by 4 publications

(6 citation statements)

References 22 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We observed a lower frequency of side effects reported after the second dose compared with the first dose. This finding contrasts with other vaccine platforms such as mRNA vaccines where in clinical trials and real-world data, the second dose appears to be more reactogenic than the first dose 17,18,22 .…”

Section: Discussioncontrasting

confidence: 72%

See 1 more Smart Citation

Vaccine Side Effects Following COVID-19 Vaccination with Inactivated Vaccines in Zimbabwe

Makadzange¹,

Gundidza²,

Lau³

et al. 2022

Preprint

View full text Add to dashboard Cite

Vaccination is one of the most effective methods for preventing morbidity and mortality from COVID-19. Vaccine hesitancy has led to a decrease in vaccine uptake; driven by misinformation, fear, and perceptions of vaccine safety. Whole inactivated vaccines have been used in one-fifth of the vaccine recipients in Africa, however there is limited real-world data on their safety. We evaluated the reported side effects and factors associated with reported side effects following vaccination with whole inactivated COVID-19 vaccines - BBiBP-CorV (Sinopharm) and CoronaVac (Sinovac). A quantitative survey evaluating attitudes and side effects from vaccination was administered to 1016 adults presenting at vaccination centers. Two follow-up telephone interviews were conducted to determine side effects after the first and second vaccination dose. Overall, the vaccine was well tolerated; 26.0% and 14.4% reported side effects after the first and second dose respectively. The most frequent local and systemic side effects were pain at the injection site and headaches respectively. Most symptoms were mild, and no participants re-quired hospitalization. Participants who perceived COVID-19 vaccines as safe or had a personal COVID-19 experience were significantly less likely to report side effects. Our findings provide data on the safety and tolerability of whole inactivated COVID-19 vaccines in an African population, providing the necessary data to create effective strategies to increase vaccination and support vaccination campaigns.

show abstract

Section: Discussioncontrasting

confidence: 72%

“…For all three interviews, approximately 12.6% of participants were people living with HIV (PLWH). The median time between follow up interview and first vaccine dose was 17 days IQR (16)(17)(18)(19). The median time between second vaccine dose and follow up interview was 10 days IQR (8 -13).…”

Section: Demographic Characteristicsmentioning

confidence: 99%

Vaccine Side Effects Following COVID-19 Vaccination with Inactivated Vaccines in Zimbabwe

Makadzange¹,

Gundidza²,

Lau³

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…We observed a lower frequency of adverse events reported after the second dose compared with the first dose. This finding contrasts with other vaccine platforms, such as mRNA vaccines where in clinical trials and real-world data, the second dose appears to be more reactogenic than the first dose [ 17 , 18 , 22 ].…”

Section: Discussionmentioning

confidence: 59%

“…Whole inactivated vaccines have played an important role in the global public health response to COVID-19 and are widely used in Africa. Although there is significant literature on adverse events following vaccination with mRNA and viral vector vaccines [ 16 , 17 , 18 , 19 , 20 ] there is limited real-world data on the side effect profile following vaccination with inactivated vaccines in Africa.…”

Section: Discussionmentioning

confidence: 99%

Vaccine Adverse Events Following COVID-19 Vaccination with Inactivated Vaccines in Zimbabwe

Makadzange¹,

Gundidza²,

Lau

et al. 2022

Vaccines

View full text Add to dashboard Cite

Vaccination is one of the most effective methods for preventing morbidity and mortality from COVID-19. Vaccine hesitancy has led to a decrease in vaccine uptake; driven by misinformation, fear, and misperceptions of vaccine safety. Whole inactivated vaccines have been used in one-fifth of the vaccine recipients in Africa, however there are limited real-world data on their safety. We evaluated the reported adverse events and factors associated with reported adverse events following vaccination with whole inactivated COVID-19 vaccines-BBiBP-CorV (Sinopharm) and CoronaVac (Sinovac). A quantitative survey evaluating attitudes and adverse events from vaccination was administered to 1016 adults presenting at vaccination centers. Two follow-up telephone interviews were conducted to determine adverse events after the first and second vaccination dose. Overall, the vaccine was well tolerated; 26.0% and 14.4% reported adverse events after the first and second dose, respectively. The most frequent local and systemic adverse events were pain at the injection site and headaches, respectively. Most symptoms were mild, and no participants required hospitalization. Participants who perceived COVID-19 vaccines as safe or had a personal COVID-19 experience were significantly less likely to report adverse events. Our findings provide data on the safety and tolerability of whole inactivated COVID-19 vaccines in an African population, providing the necessary data to create effective strategies to increase vaccination and support vaccination campaigns.

show abstract

“…This has not affected vaccination schedules in most countries, with clear promotion of vaccination for people with asthma, although the Italian Society of Allergy, Asthma and Clinical Immunology recommend that people with uncontrolled asthma may first require review in an allergy clinic. 77…”

Section: Asthma and Vaccination Against Covid-19mentioning

confidence: 99%

Covid‐19 pandemic and asthma: What did we learn?

Bloom

2023

Respirology

View full text Add to dashboard Cite

This review addresses some of the major lessons we have learnt regarding asthma and the covid-19 pandemic, including susceptibility to SARS-CoV-2 infection and severe covid-19, potentially protective factors, comparison to other respiratory infections, changes in healthcare behaviour from the perspective of patients and clinicians, medications to treat or prevent covid-19, and post-covid syndrome.

show abstract

Incidence and Characteristics of Adverse Events after COVID-19 Vaccination in a Population-Based Programme

Cited by 4 publications

References 22 publications

Vaccine Side Effects Following COVID-19 Vaccination with Inactivated Vaccines in Zimbabwe

Vaccine Side Effects Following COVID-19 Vaccination with Inactivated Vaccines in Zimbabwe

Vaccine Adverse Events Following COVID-19 Vaccination with Inactivated Vaccines in Zimbabwe

Covid‐19 pandemic and asthma: What did we learn?

Contact Info

Product

Resources

About